Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
11.52
-0.01 (-0.09%)
At close: Jul 25, 2025, 4:00 PM
11.52
0.00 (0.02%)
After-hours: Jul 25, 2025, 5:18 PM EDT
Nurix Therapeutics Employees
Nurix Therapeutics had 286 employees as of November 30, 2024. The number of employees increased by 2 or 0.70% compared to the previous year.
Employees
286
Change (1Y)
2
Growth (1Y)
0.70%
Revenue / Employee
$309,024
Profits / Employee
-$724,895
Market Cap
880.70M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Nov 30, 2024 | 286 | 2 | 0.70% |
Nov 30, 2023 | 284 | -13 | -4.38% |
Nov 30, 2022 | 297 | 55 | 22.73% |
Nov 30, 2021 | 242 | 107 | 79.26% |
Nov 30, 2020 | 135 | 42 | 45.16% |
Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NRIX News
- 13 days ago - Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors - Seeking Alpha
- 17 days ago - Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 19 days ago - European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) - GlobeNewsWire
- 7 weeks ago - Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - GlobeNewsWire
- 7 weeks ago - Sanofi Exercises License Extension Option to Nurix's STAT6 Program - GlobeNewsWire
- 2 months ago - Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire